Safety and effectiveness of insulin detemir in type 2 diabetes: Results from the ASEAN cohort of the A1chieve study
Diabetes Research and Clinical Practice, pages S10 - S16
Published online Aug-2013
To determine the safety and effectiveness of insulin detemir (IDet) in type 2 diabetes patients from the ASEAN cohort of the A1chieve study.
Patients from Indonesia, Malaysia, Philippines and Singapore prescribed IDet at the discretion of their physicians were included. The primary outcome was the incidence of serious adverse drug reactions including major hypoglycaemia over 24 weeks. Secondary endpoints included changes in the frequency of hypoglycaemia, serious adverse events and effectiveness assessments.
This sub-analysis included 1540 patients (insulin-naive, 1239; insulin-experienced, 301) with mean age ± SD 56.4±10.9 years, BMI 25.4±4.6kg/m2 and diabetes duration 6.9±5.3 years. Insulin-naive patients received a baseline IDet dose of 0.24±0.11U/kg titrated up to 0.37±0.21 U/kg by Week 24. The pre-study insulin dose in insulin-experienced patients was 0.41±0.25 U/kg and baseline IDet dose was 0.31±0.24U/kg titrated up to 0.40±0.20 U/kg by Week 24. Overall hypoglycaemia decreased from 1.73 to 0.46 events/patient-year from baseline to Week 24 (change in proportion of patients affected, p < 0.0001). At Week 24, 1 major hypoglycaemic event was reported in 1 insulin-experienced patient. IDet significantly improved glucose control (p < 0.001) at Week 24. The lipid profile and systolic blood pressure improved (p < 0.001) and body weight did not change significantly. Quality of life was positively impacted (p < 0.001).
IDet was well-tolerated and improved glycaemic control without increasing the risk of hypoglycaemia or weight gain.
Keywords: ASEAN, Type 2 diabetes, Insulin detemir.
- 1 International Diabetes Federation. IDF Diabetes Atlas. 5th edn. Brussels, Belgium; 2011, updated 14 November 2012.
- 2 SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-1596 Crossref.
- 3 K Niswender. Early and aggressive initiation of insulin therapy for type 2 diabetes: What is the evidence?. Clin Diab. 2009;27:60-68 Crossref.
- 4 American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care. 2011;34(Suppl 1):S11-S61 Crossref.
- 5 K Khunti, S Caputo, T Damci, GJ Dzida, Q Ji, M Kaiser, et al., on behalf of the SOLVE Study Group. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes Obes Metab. 2012;14(12):1129-1136 Crossref.
- 6 A Dornhorst, HJ Lüddeke, S Sreenan, P Kozlovski, JB Hansen, BJ Looij, et al., PREDICTIVE Study Group. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract. 2008;62(4):659-665 Crossref.
- 7 P Home, NE Naggar, M Khamseh, G Gonzalez-Galvez, C Shen, P Chakkarwar, et al. An observational non-interventional study of patients with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res Clin Pract. 2011;94:352-363 Abstract, Full-text, PDF, Crossref.
- 8 M Evans, PM Schumm-Oraeger, J Vora, AB King. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab. 2011;13(8):677-684 Crossref.
- 9 M Peyrot, AH Barnett. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab. 2012;14(12):1181-1187
- 10 C Mathieu. Engineering basal insulin – clinical evidence translating to clinical experience. JAPI. 2009;57:16-21
- 11 E Paz-Pacheco. Diabetes clinical practice guideline (CPGs) for the ASEAN region: Country initiatives for collectively enhanced diabetes care in the region. JAFES. 2011;26(1):36-37 Crossref.
- 12 K Raslova, M Bogoev, I Raz, G Leth, MA Gall, N Hancu. Insulin detemir and insulin aspart: a promising basal–bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004;66(2):193-201 Crossref.
- 13 K Hermansen, M Davies, T Derezinski, G Martinez Ravn, P Clausen, P Home. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269-1274 Crossref.
- 14 JP Vandenbroucke. What is the best evidence for determining harms of medical treatment?. CMAJ. 2006;174(5):645-646 Crossref.
a University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia
b Universiti Sains Malaysia, Kelantan, Malaysia Universiti Sains Malaysia, Kelantan, Malaysia
c Novo Nordisk Pharma Malaysia Sdn Bhd, Kuala Lumpur, Malaysia Novo Nordisk Pharma Malaysia Sdn Bhd, Kuala Lumpur, Malaysia
d Cardinal Santos Medical Center, San Juan, Metro Manila, Philippines Cardinal Santos Medical Center, San Juan, Metro Manila, Philippines
e Department of Medicine, Yong Loo Ling School of Medicine, National University of Singapore, Singapore Department of Medicine, Yong Loo Ling School of Medicine, National University of Singapore, Singapore
Corresponding author at: SpPD-KEMO, Division of Endorinology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia. Tel.: +62 21 390 7703; fax: +62 21 392 8659
© 2013 Published by Elsevier B.V.